Evaluation of different lansoprazole formulations for nasogastric or orogastric administration

Adekemi Olabisi, Julie L. Chen, Maya Garala

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Critically ill patients who require treatment with proton pump inhibitors are often unable to swallow solid dosage forms and have nasogastric (NG) or orogastric (OG) tube placement. Many of these patients will need medications in a liquid dosage form for easy administration. The aim of this study was to determine which extemporaneous preparation of lansoprazole is least likely to cause NG or OG tube blockage. Methods: Lansoprazole capsules, oral disintegrating tablets, and packets were each dissolved in apple juice, cranberry juice, orange juice, ginger ale, water, and 8.4% sodium bicarbonate (NaHCO3). The resulting suspension was individually passed through an 18-French NG tube and collected in a graduated cylinder. The tubes were then inspected for clots. The amount of drug retrieved from the cylinder was rated as none, partial, or complete. The physical consistency and pH changes of the suspension were assessed for stability at 0, 2, 5, 10, and 15 minutes. Results: Complete drug retrieval and no clots were observed when any of the lansoprazole dosage forms were mixed with 8.4% NaHCO3 or when the disintegrating tablet was mixed in any of the solutions. The pH of each admixture remained fairly constant over 15 minutes, but the packet-in-water combination showed a significant lowering in pH immediately after mixing. Conclusion: The use of NaHCO3 to make suspension for any lansoprazole formulation is associated with the least likelihood of tube blockage or pH variations. Thus, it may be the preferred delivery vehicle for NG/OG administration of lansoprazole, unless the Solutab is available.

Original languageEnglish (US)
Pages (from-to)537-542
Number of pages6
JournalHospital Pharmacy
Volume42
Issue number6
StatePublished - Jun 2007

Fingerprint

Lansoprazole
Dosage Forms
Suspensions
Tablets
Vaccinium macrocarpon
Ginger
Sodium Bicarbonate
Water
Proton Pump Inhibitors
Malus
Deglutition
Critical Illness
Pharmaceutical Preparations
Capsules
Liquids

Keywords

  • Enteral
  • Nasogastric tube
  • Orogastric tube
  • Proton pump inhibitors

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Evaluation of different lansoprazole formulations for nasogastric or orogastric administration. / Olabisi, Adekemi; Chen, Julie L.; Garala, Maya.

In: Hospital Pharmacy, Vol. 42, No. 6, 06.2007, p. 537-542.

Research output: Contribution to journalArticle

Olabisi, Adekemi ; Chen, Julie L. ; Garala, Maya. / Evaluation of different lansoprazole formulations for nasogastric or orogastric administration. In: Hospital Pharmacy. 2007 ; Vol. 42, No. 6. pp. 537-542.
@article{7583f6b5cd8e4e9597e90e6e5ad6be64,
title = "Evaluation of different lansoprazole formulations for nasogastric or orogastric administration",
abstract = "Background: Critically ill patients who require treatment with proton pump inhibitors are often unable to swallow solid dosage forms and have nasogastric (NG) or orogastric (OG) tube placement. Many of these patients will need medications in a liquid dosage form for easy administration. The aim of this study was to determine which extemporaneous preparation of lansoprazole is least likely to cause NG or OG tube blockage. Methods: Lansoprazole capsules, oral disintegrating tablets, and packets were each dissolved in apple juice, cranberry juice, orange juice, ginger ale, water, and 8.4{\%} sodium bicarbonate (NaHCO3). The resulting suspension was individually passed through an 18-French NG tube and collected in a graduated cylinder. The tubes were then inspected for clots. The amount of drug retrieved from the cylinder was rated as none, partial, or complete. The physical consistency and pH changes of the suspension were assessed for stability at 0, 2, 5, 10, and 15 minutes. Results: Complete drug retrieval and no clots were observed when any of the lansoprazole dosage forms were mixed with 8.4{\%} NaHCO3 or when the disintegrating tablet was mixed in any of the solutions. The pH of each admixture remained fairly constant over 15 minutes, but the packet-in-water combination showed a significant lowering in pH immediately after mixing. Conclusion: The use of NaHCO3 to make suspension for any lansoprazole formulation is associated with the least likelihood of tube blockage or pH variations. Thus, it may be the preferred delivery vehicle for NG/OG administration of lansoprazole, unless the Solutab is available.",
keywords = "Enteral, Nasogastric tube, Orogastric tube, Proton pump inhibitors",
author = "Adekemi Olabisi and Chen, {Julie L.} and Maya Garala",
year = "2007",
month = "6",
language = "English (US)",
volume = "42",
pages = "537--542",
journal = "Hospital Pharmacy",
issn = "0018-5787",
publisher = "Facts and Comparisons",
number = "6",

}

TY - JOUR

T1 - Evaluation of different lansoprazole formulations for nasogastric or orogastric administration

AU - Olabisi, Adekemi

AU - Chen, Julie L.

AU - Garala, Maya

PY - 2007/6

Y1 - 2007/6

N2 - Background: Critically ill patients who require treatment with proton pump inhibitors are often unable to swallow solid dosage forms and have nasogastric (NG) or orogastric (OG) tube placement. Many of these patients will need medications in a liquid dosage form for easy administration. The aim of this study was to determine which extemporaneous preparation of lansoprazole is least likely to cause NG or OG tube blockage. Methods: Lansoprazole capsules, oral disintegrating tablets, and packets were each dissolved in apple juice, cranberry juice, orange juice, ginger ale, water, and 8.4% sodium bicarbonate (NaHCO3). The resulting suspension was individually passed through an 18-French NG tube and collected in a graduated cylinder. The tubes were then inspected for clots. The amount of drug retrieved from the cylinder was rated as none, partial, or complete. The physical consistency and pH changes of the suspension were assessed for stability at 0, 2, 5, 10, and 15 minutes. Results: Complete drug retrieval and no clots were observed when any of the lansoprazole dosage forms were mixed with 8.4% NaHCO3 or when the disintegrating tablet was mixed in any of the solutions. The pH of each admixture remained fairly constant over 15 minutes, but the packet-in-water combination showed a significant lowering in pH immediately after mixing. Conclusion: The use of NaHCO3 to make suspension for any lansoprazole formulation is associated with the least likelihood of tube blockage or pH variations. Thus, it may be the preferred delivery vehicle for NG/OG administration of lansoprazole, unless the Solutab is available.

AB - Background: Critically ill patients who require treatment with proton pump inhibitors are often unable to swallow solid dosage forms and have nasogastric (NG) or orogastric (OG) tube placement. Many of these patients will need medications in a liquid dosage form for easy administration. The aim of this study was to determine which extemporaneous preparation of lansoprazole is least likely to cause NG or OG tube blockage. Methods: Lansoprazole capsules, oral disintegrating tablets, and packets were each dissolved in apple juice, cranberry juice, orange juice, ginger ale, water, and 8.4% sodium bicarbonate (NaHCO3). The resulting suspension was individually passed through an 18-French NG tube and collected in a graduated cylinder. The tubes were then inspected for clots. The amount of drug retrieved from the cylinder was rated as none, partial, or complete. The physical consistency and pH changes of the suspension were assessed for stability at 0, 2, 5, 10, and 15 minutes. Results: Complete drug retrieval and no clots were observed when any of the lansoprazole dosage forms were mixed with 8.4% NaHCO3 or when the disintegrating tablet was mixed in any of the solutions. The pH of each admixture remained fairly constant over 15 minutes, but the packet-in-water combination showed a significant lowering in pH immediately after mixing. Conclusion: The use of NaHCO3 to make suspension for any lansoprazole formulation is associated with the least likelihood of tube blockage or pH variations. Thus, it may be the preferred delivery vehicle for NG/OG administration of lansoprazole, unless the Solutab is available.

KW - Enteral

KW - Nasogastric tube

KW - Orogastric tube

KW - Proton pump inhibitors

UR - http://www.scopus.com/inward/record.url?scp=34250800271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250800271&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34250800271

VL - 42

SP - 537

EP - 542

JO - Hospital Pharmacy

JF - Hospital Pharmacy

SN - 0018-5787

IS - 6

ER -